The FDA issued the first complete response letter rejecting the sNDA last June.

FORBES: FDA Again Rejects ACS Indication for Rivaroxaban (Xarelto)

Besides biotech, gurus were also buying new positions in software companies, most notably Shanda Interactive Entertainment (nasdaq: SNDA - news - people ) and Epicor Software (nasdaq: EPIC - news - people ).

FORBES: Gurus Buy Biotech And Software, Sell Health Care